NBS

Neostem Up 7.6%, Penny Stock Attracts Attention (NBS)

Published on Fri, 05/03/2013 - 12:25
By Adrienne Chilton in Market movers, NBS, amex:nbs, neostem, penny stocks
NBS

By Adrienne Chilton
achilton@fnno.com

Hot Stock: Neostem, Shares Drop 17.5% (NBS)

Published on Tue, 04/30/2013 - 10:25
By Peter Chu in Market movers, NBS, amex:nbs, neostem, penny stocks
NBS

By Peter Chu
pchu@fnno.com

NeoStem Receives Over $1,700,000 in Department of Defense Funding For its VSEL Technology

Published on Mon, 08/08/2011 - 10:04
By FNNO Staff in General Interest, NBS, business, contract, department of defense, finance, market, neostem, news, price, share, stock, News Update

The award will support an investigation of a unique stem cell population, Very Small Embryonic-Like stem cells, for its bone building and regenerative effects in the treatment of osteoporosis.

business, contract, department of defense, finance, market, neostem, news, price, share, stock

NeoStem (AMEX:NBS) announced that the Department of Defense has awarded NeoStem $1.78M to be applied towards funding the company's VSEL Technology.

By FNNO Staff
fnnonline@gmail.com

Stock Offer Pricing Causes Neostem To Sink 21%

Published on Tue, 07/19/2011 - 12:13
By FNNO Staff in General Interest, NBS, business, income, investment, market, nbs, news, shares, stocks, trade, News Update

Neostem plans to sell 13.75 million security units at $1.20 per unit. Each unit will consist of one common share and a warrant to buy 0.75 of a common share at $1.45.

Neostem is looking to gross $16.5 million from the transaction, which should close around July 22.

Neostem has a potential upside of 281% based on a current price of $1.05 and an average consensus analyst price target of $4.

business, income, investment, market, nbs, news, shares, stocks, trade

Shares of Neostem Inc. (AMEX:NBS) fell 21% to $1.04 after it priced a stock offering below Monday's closing price of $1.32.

By FNNO Staff
fnnonline@gmail.com

NeoStem Concludes Acquisition of Progenitor Cell Therapy

It serves the cell therapy community with cGMP state-of-the art cell therapy manufacturing facilities, and processing and storage facilities for stem cells collected from the umbilical cord at birth. NBS expects that Progenitor Ce

Shares are down 1.33% or $0.02 to $1.48.

beat, busines, buy, earn, earnings, economy, eps, estimate, financial news, high, invest, investing, low, market analysis, miss, net, price, profit, project, sale, sell revenue forecast income, stem cells, stock, trading

Neostem (NBS) announced today that it has concluded its merger transactionn with Progenitor Cell Therapy, a private cell therapy company operating in the east and west coast of the U.S.

By FNNO Staff
fnnonline@gmail.com

Latest News from FNNO

Shares of Zions Bancorporation Rise Abov...

Shares of Zions Bancorporation (NASDAQ:ZION) traded at a new 52-week high today of $27. ...

Shares of YRC Worldwide Have Risen Above...

Shares of YRC Worldwide (NASDAQ:YRCW) traded at a new 52-week high today of $21.44. Ap ...

Shares of Crosstex Energy Rise to a New ...

Shares of Crosstex Energy (NASDAQ:XTXI) traded at a new 52-week high today of $20.50. ...

Weyerhaeuser: The Winning Streak Continu...

Weyerhaeuser (NYSE:WY) traded today at a new 52-week high of $32.67. So far today appr ...

Shares of Web.com Group Inc Rise to a Ne...

Shares of Web.com Group Inc (NASDAQ:WWWW) traded today at $22.84, breaking its 52-week ...

West Pharmaceutical Services Looks to Co...

West Pharmaceutical Services (NYSE:WST) traded today at a new 52-week high of $68.67. ...

Shares of Watsco Rise Above Previous 52-...

Watsco (NYSE:WSO) traded today at a new 52-week high of $89.10. Approximately 58,000 s ...

Watch for Continued Gains in Shares of W...

Shares of WPX Energy (NYSE:WPX) traded at a new 52-week high today of $19.84. Approxim ...

Most Popular Video News